RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
TG Therapeutics Stock

TG Therapeutics Dividend 2024

TG Therapeutics Dividend

0 USD

TG Therapeutics Dividend yield

Ticker

TGTX

ISIN

US88322Q1085

WKN

A1JXW7

How much dividend does TG Therapeutics 2024 pay?

According to the latest status from October 2024, TG Therapeutics paid a total of 0 USD per share in dividends within the last 12 months. With the current TG Therapeutics price of 22.83 USD, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical TG Therapeutics Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the TG Therapeutics Dividend Safe?

TG Therapeutics has been increasing the dividend for 0 years.

Over the past 10 years, TG Therapeutics has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Dividend Details

Understanding TG Therapeutics's Dividend Distributions

TG Therapeutics’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining TG Therapeutics's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

TG Therapeutics's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in TG Therapeutics’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

TG Therapeutics Aktienanalyse

What does TG Therapeutics do?

TG Therapeutics Inc is a biopharmaceutical company based in New York City, USA. The company was founded in 2012 and focuses on the development and commercialization of innovative therapy options for various types of cancer and autoimmune diseases. TG Therapeutics was founded as a result of a collaboration between Michael S. Weiss, an experienced investment banker and biotechnology manager, and Laurence N. Charous, an oncologist and clinical researcher. The company has roots in two predecessor companies: Manhattan Pharmaceuticals and LFB Biotechnologies. Both had failed, and TG rose from their remains. TG Therapeutics' business model is to develop a new therapy option by combining drugs of different drug classes that target the needs of patients with specific cancer conditions. The dual blockade approach, which simultaneously inhibits various signaling pathways that sustain tumor cells, is particularly promising. TG Therapeutics operates a diversified portfolio strategy and has several drug candidates in different stages of development for numerous cancer conditions, including diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma, as well as autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. TG Therapeutics' main products for cancer treatments currently are umapalisib and umbralisib, both of which are PI3K delta inhibitors and are being developed for the treatment of non-Hodgkin lymphomas and chronic lymphocytic leukemia. TG-1101 (Ublituximab) is a CD20-targeted antibody therapy used in lymphomas and autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. TG Therapeutics' research and development efforts are driven by an experienced team of oncologists and scientists, including CEO Michael S. Weiss. The company maintains close relationships with academic institutions and research facilities. TG Therapeutics holds a broad patent portfolio covering technologies and compounds that can be used in cancer and autoimmune disease treatment. In 2020, TG Therapeutics' revenue reached approximately $109 million, compared to $14 million in the previous year. This increase in revenue was due to the sales of umbralisib. However, the company has not yet received FDA approval for any of its drugs in the US. TG Therapeutics expects that the future success of the company will be based on the clinical activity of its pipeline, market acceptance of its products, and successful completion of studies and regulatory approvals. As of December 31, 2020, TG Therapeutics had 248 employees. The company's leading body, the board of directors, consists of an experienced team of executives and advisors, including Chairman and CEO Michael S. Weiss, CFO Sean A. Power, CMO Adam D. Feuerstein, and COO Scott T. Smith. TG Therapeutics has had a tumultuous past, but the company can now look forward to a promising pipeline and a very strong financial position. The research and development of this biopharmaceutical company are promising, and it remains to be seen which of the research products will actually break through and be introduced to the market. TG Therapeutics is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The TG Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Frequently Asked Questions about TG Therapeutics stock

How much dividend does TG Therapeutics pay?

Over the past 12 months, TG Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, TG Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of TG Therapeutics?

The current dividend yield of TG Therapeutics is .

When does TG Therapeutics pay dividends?

TG Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of TG Therapeutics?

TG Therapeutics paid dividends every year for the past 0 years.

What is the dividend of TG Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is TG Therapeutics located?

TG Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von TG Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of TG Therapeutics from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did TG Therapeutics pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of TG Therapeutics in the year 2023?

In the year 2023, TG Therapeutics distributed 0 USD as dividends.

In which currency does TG Therapeutics pay out the dividend?

The dividends of TG Therapeutics are distributed in USD.

Andere Kennzahlen von TG Therapeutics

Our stock analysis for TG Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of TG Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.